News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sandoz, Inc. Initiates Two More Phase III Amgen (AMGN) Biosimilar Trials



1/19/2012 8:13:53 AM

Sandoz announced today that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen(R)) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta(R)). The filgrastim study is to evaluate the efficacy and safety of Sandoz's biosimilar filgrastim versus Neupogen(R) in breast cancer patients eligible for myelosuppressive chemotherapy treatment. It is expected to support extension of commercialization to the US, the largest global market for biologics. Sandoz's filgrastim biosimilar is already marketed under the brand name Zarzio(R) in more than 30 countries outside the United States.

Read at Reuters
Read at News Release
Read at InPharm.com
Read at EconomicTimes


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES